Morphological changes after combined administration of isoproterenol and K+,Mg2+-aspartate as a physiological Ca2+ antagonist.
The possibility of prevention of isoproterenol (ISO)-induced morphological changes by Ca2+ antagonists was investigated in the heart muscle of dogs. ISO in a dose of 7 mg/kg caused marked histochemical and electron microscopical necrotic changes. K+, Mg2+ aspartate (K,Mg-ASP) administered alone in a dose of 100 mg/kg changed slightly almost all cell components. K,Mg-ASP treatment applied prior to administration of ISO after 24 hours resulted in an improvement of the ultrastructure, which generally exhibited marked restoration resembling metabolic regeneration and/or enhanced metabolic activity.
D000818:Animals; D001224:Aspartic Acid / Q000627:therapeutic use; D002118:Calcium / Q000037:antagonists & inhibitors; D009202:Cardiomyopathies / Q000139:chemically induced / Q000473:pathology* / Q000517:prevention & control; D004285:Dogs; D006003:Glycogen / Q000378:metabolism; D007545:Isoproterenol / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008274:Magnesium / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism; D010088:Oxidoreductases / Q000378:metabolism; D011188:Potassium / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D001224:Aspartic Acid; D006003:Glycogen; D010088:Oxidoreductases; D008274:Magnesium; D007545:Isoproterenol; D011188:Potassium; D002118:Calcium